WCAS To Sell Ameripath

Welsh, Carson, Anderson & Stowe has agreed to sell diagnostics testing company Ameripath to Quest Diagnostics (NYSE: DGX). The deal is valued at approximately $2 billion, including $770 million in debt. The deal is expected to close later this quarter. WCAS acquired Ameripath in 2003 for approximately $840 million. www.ameripath.com